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Abstract 
Oral liquids are often preferred for drug administration to patients for whom swallowing is difficult, 
however formulating modified release versions can be challenging. A potential route to achieve 
modified release in oral liquids is by using fluid (sheared) gels formed by introducing a shear field 
during gelation in gel-forming biopolymers. These fluid gels can act as pourable viscoelastic fluids 
but retain true gel micro/nano structure. Here, we have demonstrated that fluid gels have potential 
as paediatric oral liquids preventing release of ibuprofen in simulated gastric fluid. Subsequent 
release at pH 7.4 was affected by the duration of exposure and magnitude of acid pH with a linear 
relationship between onset of release and the preceding acidic exposure duration. Delayed release 
was a result of increasing gel stiffness, a consequence of the acidity of the initial release media and 
exposure time. A much faster release rate was measured when exposure time in acid was 10 min 
compared with 60 min. This study highlights the potential to design fluid gels that are tuned to have 
a specified stiffness at a particular pH and exposure time. This could enable the preparation oral 
liquids with modified release behaviour. 
 
 
 
 
 
 
 
 
1. Introduction 1 
There is an ever increasing demand for the development of age appropriate dosage forms, especially 2 
for paediatric patients and older adults who have difficulties in swallowing. This is most apparent in 3 
modified release formulations where the functional excipients responsible for controlling drug 4 
release can become ineffective due to manipulation prior to administration to children. Even over 5 
the counter antipyretic formulations have an increased risk of side effects in children.  Worryingly, 6 
there are very few oral modified-release drug delivery platforms suitable for administration to 7 
paediatrics. Generally, for children and patients who find swallowing is difficult, syrup-based oral 8 
liquids are the preferred dosage form however formulating these dosage forms to have modified 9 
release properties can be challenging. Recently researchers have looked to develop such dosage 10 
forms using enteric coated micro-particles (Dalmoro et al., 2010) and ion exchange resins (Cuña et 11 
al., 2000) however these systems are often costly, suffer from poor mouth feel and are only suitable 12 
for use with specific drugs. There is therefore a real need for alternative formulations.  A potential 13 
route to achieve modified release in oral liquids is by using polysaccharide solutions which undergo 14 
a sol gel transition on exposure to stomach acid. Indeed several authors have evaluated the oral 15 
sustained delivery of drugs such as theophylline, ambroxol, paracetamol and cimetidine in various 16 
in situ gelling polysaccharides which have included xyloglucan (Miyazaki et al., 2003; Itoh et al., 17 
2008; Itoh et al., 2010), pectin (Itoh et al., 2008; Kubo et al., 2004; Miyazaki et al., 2005; Kubo et 18 
al., 2005), and sodium alginate (Itoh et al., 2010; Kubo et al., 2003). Although these systems have 19 
shown some promise as vehicles there are issues associated with their use such as leaching of water 20 
soluble drugs and lengthy gastric retention due to large bulk gel formation in situ (Kubo et al., 21 
2003). These issues could potentially be overcome by using fluid gels.   22 
Fluid gels (also referred to as sheared gels) can be defined as suspensions of gel particles prepared 23 
by introducing a shear field while gelation is occurring in biopolymer solutions. These fluid gels 24 
can be formulated so the bulk material acts as a pourable viscoelastic fluid whilst retaining a cross-25 
linked gel microstructure within the particles. The formation of these gelled particles has been 26 
previously described by a nucleation and growth mechanism, with the applied shear field limiting 27 
the molecular ordering to within individual gel particles by physically ensuring that the original 28 
formed gel nucleation sites remain separate from one another (Norton et al., 1999).  Along with the 29 
bulk viscosity, the size and strength of these micron-sized, gelled particles can also be controlled by 30 
varying the concentration of polymer and shearing rate used during production (Gabriele et al 2009; 31 
Fernández Farrés et al., 2014). This creates an attractive opportunity to incorporate drugs into an 32 
acid-resistant fluid gel which could potentially delay release in the stomach.  33 
Gellan gum is a biopolymer particularly suited for producing fluid gels for such applications. It is a 34 
microbial exopolysaccharide produced by Sphingomonas elodea (Doner  et al.,1997; Dai et al. 35 
2008) and consists of repeating tetrasaccharide units of glucose, glucuronic acid, glucose and 36 
rhamnose residues (Chandrasekaran et al., 1988). Gellan gum is an EU approved food additive 37 
(E418) that has been investigated by several groups for applications in pharmaceuticals (Deasy and 38 
Quigley, 1991; Carlfors et al., 1998) and as a biomaterial (Smith et al., 2007; Oliveira et al., 2010; 39 
Jahromi et al., 2011). At temperatures above 85 °C the gellan gum exists as a random coil, which 40 
forms helical structures upon cooling resulting in a “weak gel” formed by tenuous association of 41 
ridged ordered structures (Norton et al., 1984) rather than by stronger associations of junction zones 42 
present in normal polysaccharide gels (Rees et., al 1982). However, on addition of ions such as 43 
hydrogen, sodium, potassium and calcium true, self-supporting gels are formed. This occurs via a 44 
mechanism of aggregation of gellan double helices either by suppression of the negatively charged 45 
groups on the polymer with monovalent ions or by direct site binding of the helices with divalent 46 
cations (Grasdalen and Smidsrod, 1987; Sworn et al., 1995; Morris et al., 2012). The mechanical 47 
properties and gelation temperature can be controlled by salt concentration and species (Ogawa, 48 
1996).  The ability of gellan gum to form acid-insoluble gels renders it a particularly attractive 49 
candidate for developing oral bioresponsive drug delivery systems. Indeed, these have been 50 
investigated in the form of gastro-retentive controlled release (Babu et al., 2010), enteric release 51 
(Smith et al., 2010) and as floating in situ gelling systems (Rajinikanth and Mishra, 2008).  52 
Furthermore oral sustained delivery using gellan solutions (which formed acid gels in the stomach) 53 
has also been explored and bioavailability from the gels formed in situ was similar to that of a 54 
commercially available suspension (Kubo et al., 2003).  Unlike tablet or capsule formulations, there 55 
is no standard technique for measuring the dissolution properties of oral liquids. Biopharmaceutical 56 
measurements of such formulations are usually performed using modified USP dissolution 57 
apparatus which can lead to high variability. This is a particularly important issue when designing 58 
medicines for children as extrapolating adult biopharmaceutical measurements is difficult due to the 59 
difference in gastrointestinal physiology in paediatric patients (Batchelor et al., 2013). Moreover, 60 
large variations in physiology within paediatric populations are also evident from birth through to 61 
adolescence (Bowles et al., 2010) which further complicates the design suitable biopharmaceutical 62 
methodologies. 63 
In the present study gellan gum fluid gels loaded with ibuprofen, (a BCS Class II drug that is 64 
currently available as modified release tablets) were investigated as a modified release oral liquid.  65 
Fluid gel formulations were investigated over a range of pH and acid exposure times to evaluate 66 
how variations in gastric physiology may impact the mechanical properties of these physiologically 67 
responsive fluid gels and the consequential release behaviour. 68 
 69 
2. Material and Methods 70 
2.1. Materials 71 
Low acyl gellan gum (KelcogelTM) was kindly donated by CP Kelco (USA). Ibuprofen powder 72 
(Ibuprofen 38) was obtained from BASF. All other materials were obtained from Sigma–Aldrich, 73 
Poole, UK.  74 
2.2. Preparation of fluid gels 75 
Fluid gels were prepared by adding low acyl gellan gum at concentrations from 0.1 to 1% w/w to 76 
deionised water at 85 °C while stirring. Once fully dissolved, the solutions were allowed to cool to 77 
~60 °C then a paediatric dose of ibuprofen (20 mg/ml) was added and the pH was adjusted to 7.4 78 
using 1 M NaOH. Solutions were then cooled further at 2 °C min-1 whilst being sheared using 79 
Bohlin Gemini Nano HR rheometer at a shear rate of 500 s-1. To evaluate the potential to vary the 80 
particle size during formulation, fluid gels were prepared with changes to the processing conditions.   81 
To investigate the effect of cooling rate, 0.75% w/w gellan gum fluid gels were prepared as 82 
described above at a fixed shear rate of 500 s-1 with cooling rates of 0.5 °C min-1,  2 °C min-1 and 10 83 
°C min-1. Similarly, to investigate the effect of shear rate, 0.75% w/w gellan gum fluid gels were 84 
prepared at a fixed cooling rate of 2 °C min-1 using shear rates of 100 s-1, 500 s-1 and 1000 s-1.  85 
2.3. Preparation of control formulations 86 
2.3.1 Viscosity test controls   87 
To ensure the fluid gel formulations had a suitable viscosity profile a marketed paediatric ibuprofen 88 
suspension was used as a standard comparison and referred to as C1. 89 
2.3.2 Dissolution test controls  90 
To ensure ibuprofen could be fully dissolved in the dissolution media (PBS pH 7.4) at the 91 
formulated dose following 20 min exposure to acid at pH 1.2 (and any delayed release was not an 92 
effect of the pKa of the ibuprofen), control solutions were prepared by adding drug (20 mg/ml) to 93 
deionized water at ~60 °C which were cooled to room temperature and the pH was adjusted to 7.4 94 
using 1 M NaOH (referred to as C2). 95 
To ensure the same grade of ibuprofen was used in all dissolution experiments formulations based 96 
upon standard ibuprofen suspensions were prepared as a control by adding 0.3% w/w xanthan gum 97 
and 0.2% w/w sorbitol to deionized water / glycerol 50:50 at 85°C while stirring (to prevent any 98 
interference with UV analysis no preservatives, colouring agents or flavours were added). Once 99 
fully dissolved, the solution was allowed to cool to ~60 °C then a paediatric dose of ibuprofen (20 100 
mg/ml) was added. The suspension was then cooled to room temperature and referred to as C3.  101 
2.4. Viscosity measurements 102 
Viscosity of all samples was determined taken at 25 °C using the Bohlin Gemini Nano HR 103 
rheometer using the 55 mm parallel plate geometry across shear rates ranging from 1 s-1 - 1000 s-1.  104 
2.5. Microscopy  105 
Fluid gel samples were imaged using an optical microscope (Keyence VHX digital microscope RZ 106 
x 250- x2500 real zoom lens in high dynamic range). Samples were prepared for imaging by 107 
dispersing the fluid gel samples in 10 ml of 50 mM CaCl2. The suspension was then centrifuged at 108 
13000 rpm and the pellet was then examined under the microscope. CaCl2 was used as the diluent 109 
during the processing of the sample prevent aggregation of the gel particles during the 110 
centrifugation step.   111 
2.6. Dissolution studies 112 
A modified USP I apparatus (baskets at a stirring rate of 100 rpm) was used to study in vitro drug 113 
release. Each formulation (5 ml) was placed into dialysis tubing (12500 MWCO) then submerged 114 
(within the baskets) in small volume vessels containing 200 ml dissolution media at pH values of 115 
1.2, 2, 3, 4, 5, and 7.4 for 20 min. The media were subsequently changed to pH 7.4 phosphate 116 
buffered saline (sodium chloride 137 mM, potassium chloride 2.7 mM, disodium hydrogen 117 
phosphate 10 mM and potassium dihydrogen phosphate 2.0 mM). All buffers used were prepared at 118 
the same ionic strength and pH 7.4 was used to represent the highest pH the formulations may 119 
encounter during intestinal transit (terminal ilium). To understand how release in simulated 120 
intestinal conditions was affected by residence time in acidic media, samples were also exposed to 121 
pH 1.2 and pH 2 environments for time periods increasing from 5 min to 120 min before changing 122 
the media to pH 7.4 and recording the subsequent onset of release. Ibuprofen standards were 123 
prepared at concentrations ranging from 10-1000 g/ml and measured using UV spectrophotometer 124 
at a wavelength of 254 nm to generate calibration curves which were plotted for all pH values. The 125 
concentration of ibuprofen released from the sample was determined from the corresponding 126 
calibration curves. All experiments were carried out in triplicate. 127 
2.7. Rheological Measurements 128 
The following rheological measurements were performed to investigate how gel stiffness changes 129 
during the in vitro dissolution tests and therefore enable correlation of stiffness (G‟) to drug release.  130 
To understand how elastic modus (G′)  was affected by residence time in acidic media, 5 ml of the 131 
formulation was placed into a dialysis tube (12500 MWCO) then submerged in 200 ml 0.1 M HCl 132 
at pH 1.2 for time periods increasing from 5 to 120 min before loading the sample on the rheometer.  133 
To study the impact the change of dissolution media (to PBS pH 7.4) has on the stiffness of the gel 134 
following exposure to acid, another set of samples was also exposed to pH 1.2 for 10 and 60 min 135 
(batch A and B respectively). The medium was then changed to pH 7.4 for a period of time from 30 136 
to 600 min for batch A and 60 to 1200 min for batch B, prior to loading on the rheometer.   137 
Rheological measurements were carried out using a Bohlin Gemini Nano HR rheometer. Oscillation 138 
mode was used to determine viscoelasticity of the gel. Mechanical spectra were obtained by taking 139 
measurements of the elastic (storage) modulus (G′), viscous (loss) modulus (G′′) and complex 140 
dynamic viscosity (*). The measurements were recorded at 10 rad/s angular frequency and 0.5% 141 
strain using a 55 mm parallel-plate geometry with a 0.5 mm gap. The strain amplitude chosen was 142 
within the linear viscoelastic region of the samples. All measurements were taken at 37 °C.  143 
2.8. Statistical analysis 144 
Statistical significance (P < 0.05) between test groups was determined by one-way analysis of 145 
variance (ANOVA) and Tukey post-hoc test using Primer of Biostatistics version 4. 146 
3. Results 147 
3.1. Rheological Measurements 148 
Using a rheometer, the formation of fluid gels can be characterised during manufacture alongside 149 
real-time measurements of the characteristic changes in viscosity that occur during formation.  150 
Figure 1 shows the relative viscosity vs temperature of a 0.1%, 0.375%, 0.5% 0.75% and 1% w/w 151 
gellan gum fluid gel during manufacture. As the temperature is decreased there is an increase in 152 
viscosity that occurs at the onset of gelation of the gellan, a maximal viscosity is then reached 153 
which is the temperature beyond which no further particles are formed (Tmax), followed by a plateau 154 
in viscosity as the formed particles are smoothed. The results indicate that the viscosity of fluid gel 155 
is concentration dependant; onset of gelation increases from ~40 °C for 0.1 % gellan gum to ~45 °C 156 
for 1% gellan gum. Furthermore, the final viscosity (at 500 s-1 and 20 °C) of the fluid gels increases 157 
with increasing concentration from ~0.01 Pas for 0.1% w/w gellan gum up to ~0.1 Pas for 1% w/w 158 
gellan gum. To evaluate the potential of gellan gum fluid gels as a modified oral liquid, samples 159 
were tested and compared with a proprietary ibuprofen suspension. The viscosity profiles of gellan 160 
gum fluid gel formulations (0.1-1 % w/w) are shown in figure 2A and have a shear thinning 161 
viscosity profile. The 0.75% fluid gel sample exhibited a viscosity profile that was most similar to 162 
that of a standard ibuprofen paediatric suspension. In addition the yield stress was sufficient to 163 
allow inversion of the fluid gel sample without any flow however following mild shaking of the 164 
sample it is easily poured on a dispensing spoon as illustrated in figure 3 (Supplementary Video 1) .  165 
This formulation was therefore used in further investigations. Dynamic small deformation 166 
oscillatory measurements of G‟ and G‟‟ (Fig 2B) highlight the viscoelasticity of the 0.75% w/w 167 
fluid gel with G‟ slightly greater than G‟‟ across a range of frequencies; this is typical „weak gel‟ 168 
rheological behaviour. Figure 3 shows the effect of cooling rate on the viscosity during formation of 169 
a 0.75% w/w fluid gel at a fixed shear rate of 500 s-1 (Fig 4A) and the effect of shear rate at a fixed 170 
cooling rate of 2 °C/min (Fig 4B). The viscosity of the fluid gels during formation increased with 171 
increasing cooling rates and viscosity decreased when shear rate was increased.  172 
 173 
3.2 Effect of gellan gum concentration  174 
Microscopy images in figure 5 reveal particle sizes of fluid gel are highly dependent on 175 
concentration. At 0.1% gellan the particles were in the region of 1-5 m and were generally 176 
spherical in shape (Fig. 5A). As the concentrations increased to 0.5% the particles had a larger, 177 
binomial size distribution with a population of micron sized particles (similar to 0.1% w/w) and a 178 
population and a population in the region of 10-20 m (Fig. 5B). At 0.75% w/w the particles appear 179 
less polydisperse than at 0.5% and more spherical with the majority of the population in the region 180 
of 20 m (Fig. 5C). When the concentration is increased further to 1% the particles were much 181 
larger and irregular in shape (Fig. 5D).   182 
 183 
3.3 Effect of cooling rate and shear rate  184 
Figure 6 shows the effect of increasing cooling rates on the particle size of 0.75% w/w at fixed 185 
shear rate of 500 s-1 (Fig 6A-C) and the effect of increasing shear rates on the particle size of same 186 
concentration of gellan at fixed cooling rate of 2 °C/min (Fig 6D-F). These micrographs indicate 187 
that a smaller particle size can be obtained by decreasing cooling rate and increasing the shear rate 188 
when forming the fluid gels. 189 
 190 
3.3 Dissolution behaviour   191 
To investigate the effects of exposure to low pH for the fluid gels a 5 ml sample of each was 192 
dispensed into 0.1M HCl at pH 1.2. A proprietary ibuprofen suspension (C1) was also used for 193 
comparison. The proprietary formulation formed a cloudy dispersion in the acid which is attributed 194 
to the poor solubility of ibuprofen at low pH. The gellan fluid gel on the other hand formed an acid 195 
gel with the ibuprofen remaining associated with the gellan. This remained as large aggregated gel 196 
pieces for over 6 hours. This was supported by dissolution experiments which showed no ibuprofen 197 
was released at pH 1.2 (results not shown) and in Figure 7 where ibuprofen crystals can be seen to 198 
remain entrapped within the fluid gel particles.   199 
Figure 8 illustrates the in vitro release of ibuprofen from different gellan gum fluid gel 200 
concentrations ranging from (0.0 % (ibuprofen alone) to 0.75% w/w) determined at pH 1.2 then the 201 
release media was changed after 20 minutes to PBS pH 7.4 . The results show that there was a small 202 
quantity of ibuprofen released in acidic media for the gels containing lower concentrations of gellan 203 
and control formulations (C2 and C3). At 0.75% w/w however, there was no release in acid medium 204 
and subsequent release was retarded in PBS for 30 min. 205 
To account for the wide variation in stomach pH found in paediatric patients, release characteristics 206 
were determined in vitro at different pH values (1.2, 2, 3, 4, 5 and 7.4) then the release medium was 207 
changed after 20 minutes to PBS pH 7.4. Figure 9 highlights that the release of ibuprofen from the 208 
gellan gum fluid gel was strongly affected by pH of the dissolution media. There was no significant 209 
difference (p > 0.05) in release between samples initially immersed in pH 7.4, pH 5 and pH 4. At 210 
pH 3 however, subsequent release of ibuprofen was retarded. The retardation of release became 211 
progressively more pronounced as the pH was dropped further, to the point where exposure to pH 212 
1.2 for just 20 min delayed the onset of drug release for a further 60 min when transferred to pH 213 
7.4.  The duration of exposure to acidic pH was shown to dramatically affect the lag time to onset of 214 
release following transfer to pH 7.4. Figure 10 illustrates the linear relationship between onset of 215 
release in pH 7.4 and the preceding exposure time at pH 1.2 and pH 2. The onset of release in pH 216 
7.4 was shown to be dramatically affected by the acidity of the initial dissolution medium taking 217 
almost 3 hours after exposure to pH 1.2 (for 2 hours) compared with  30 minutes to onset of release 218 
following exposure to pH 2 (for 2 hours). This lag time was shown to be dependent on gel stiffness. 219 
Figure 11 shows onset of release time rises exponentially with increase in G‟, which in turn is 220 
dependent on exposure time to pH 1.2 as highlighted in figure 12. Interestingly, when the fluid gel 221 
was transferred to PBS pH 7.4 following 10 minutes in pH 1.2 medium, the gel stiffness continued 222 
to increase, albeit at a slower rate, until a plateau was reached (following 90 minutes in pH 7.4) 223 
where G‟ is approximately 1200 Pa.  When the gel was exposed to pH 1.2 for 60 minutes the 224 
stiffness was almost an order of magnitude greater than after 10 minutes exposure. However 225 
following transfer to PBS pH 7.4 the stiffness gradually decreased over a period of 180 minutes to 226 
the plateau where G‟ is approximately 1200 Pa. The relationship between gel stiffness and release 227 
in pH 7.4 is highlighted in figure 13. Following 60 minutes exposure to 0.1 M HCl the gel stiffness 228 
was 8000 Pa which gradually decreased on transfer to PBS. No released drug was detected until the 229 
stiffness of the gel had reduced to ~2000 Pa (which took 2 hours), following which zero order 230 
release 0.15 mg/min was apparent (Fig. 13A). When the sample was exposed to pH 1.2 for 10 231 
minutes, the gel stiffness was only ~600 Pa and gradually increased to ~1300 Pa on transfer to PBS 232 
pH 7.4. In this system the zero order drug release occurred within 40 minutes and at an increased 233 
rate of 0.44 mg/min (Fig. 13B). After this time, the gel disintegrated and was no longer included in 234 
this study. These results highlight that increased gel stiffness can reduce the release rate.   235 
 236 
4. Discussion 237 
The use of fluid gels as a platform technology for pharmaceutical formulations has great potential 238 
due to the tuneable mechanical properties and their ease of manufacture. It has been previously 239 
shown that fluid gels can be prepared with many different biopolymers including gelatin (de 240 
Carvalho and Djabourov, 1997), agarose (Norton et al., 1998), -carrageenan (Garrec and Norton, 241 
2012; Gabriele et al., 2009) and gellan gum (Sworn et al., 1995). Most of these investigations have 242 
been focused towards applications in foods to improve stability and improve texture. Here we have 243 
investigated the potential of gellan gum fluid gels as a modified release oral drug delivery system. 244 
The preparation of fluid gels is a simple process, producing gelled particles that are dispersed in an 245 
un-gelled medium. Production using a rheometer allows the cooling rate and the shear rate to be 246 
accurately controlled and the characteristic change in viscosity monitored (the process however, is 247 
easily carried out on a larger scale using application of shear). When the gellan gum fluid gels were 248 
formed containing ibuprofen, the onset of ordering increased with increasing gellan concentration 249 
(Fig 1) which can be explained by the consequential increase in concentration of the counterions to 250 
the charged group of the polymer promoting aggregation (Morris et al 2012). Interestingly, this 251 
onset of ordering occurs at a slightly lower temperature that has been previously reported for gellan 252 
gum fluid gels without a drug load (Sworn et al., 1995). This is thought to be due to the competitive 253 
inhibition by the negatively charged ibuprofen binding some of the Na+ ions (introduced during pH 254 
adjustment with NaOH) reducing the overall ionic strength of the bulk, consequently reducing the 255 
viscosity and gelation temperature. Once manufactured, the bulk fluid gels containing ibuprofen 256 
showed shear thinning behaviour similar to that of a proprietary paediatric oral ibuprofen 257 
suspension with the 0.75% w/w fluid gel having the closest match (Fig 2). However, at very low 258 
shear rates the viscosity was sufficient for the preparation to be inverted without any steady state 259 
flow as illustrated in figure 3 (Supplementary Video 1). This is due to the weak gel properties of the 260 
ibuprofen gellan fluid gel (Fig 2B) which are thought to be a result of particle-particle interactions 261 
(Garrec et al., 2013).  262 
 Oral liquid formulations with relatively high values of zero shear viscosity that rapidly shear thin to 263 
enable dispensing would be greatly beneficial by suspending the drug more efficiently during 264 
product storage while not impacting on the ease of administration. Furthermore, producing oral 265 
liquid formulations with modified release properties would provide an alternative dosage form for 266 
paediatric patients in particular. The physical properties of gellan gum fluid gels can be tuned by 267 
simply changing the concentration of the polymer or by the rate of cooling and/or shear rate during 268 
fluid gel formation (Fig 4). This has previously been demonstrated in food based applications with 269 
agarose and carrageenan fluid gels (Norton et al 1998; Gabriele et al 2009). This allows the particle 270 
size to be controlled as shown in figures 5 and 6. Gellan gum has previously shown promise as a 271 
sustained release oral liquid which gels in situ (Miyazaki et al., 1999). In this study we present a 272 
gellan gum oral liquid which was formulated to have a physically cross-linked microstructure prior 273 
to exposure to an acidic gastric environment. The weak acid gel contains pre-gelled particles and 274 
ungelled gellan effectively immobilising the pre-gelled particles. This system was shown to prevent 275 
the dispersion of ibuprofen in the gastric fluid as occurred with a proprietary oral liquid and the 276 
drug remained associated with the gellan gum for over 6 hours at pH 1.2. A problem often 277 
associated with hydrogel drug delivery systems is drug leaching through the pores of the gel. In this 278 
system however, the poor solubility of ibuprofen resulted in precipitation within the gel when 279 
exposed to 0.1M HCl pH 1.2, illustrated by the opaque nature of the gel with the precipitated drug 280 
particles remaining entrapped within gel particles as illustrated in figure 7. 281 
To develop a modified release oral liquid designed particularly for children it is vitally important to 282 
take into account paediatric gastrointestinal physiology when designing in vitro biopharmaceutical 283 
tests. Variables such as stomach acid volume, gastric pH and small intestinal transit time, which are 284 
important for drug release, are well documented (Bowles et al., 2010). For example, in paediatric 285 
patients the age at which gastric acid secretion reaches adult values is often quoted as 6 months, 286 
however in reality the pH remains variable and the time that intragastric pH is maintained below pH 287 
2 increases as a function of age. Nagita et al. (1996) reported that gastric acidity rapidly increased 288 
from infancy to 3 years of age and then slowly increased and attained adult levels (< pH 2 for 65% 289 
of a 24 h period) by adolescence (age 14). In vitro release data shown in figure 8 reveal that even at 290 
concentrations as low as 0.1%, gellan fluid gels have the ability to retard the release of ibuprofen 291 
following 20 minutes exposure to 0.1 M HCl pH 1.2 compared with the control formulations (C2 292 
and C3). There is however, still some ibuprofen (approximately 5%) released while exposed to pH 293 
1.2. Increasing gellan concentration further slows release and at 0.75%, no ibuprofen was measured 294 
during acid exposure. Moreover, when the medium was changed to pH 7.4, there was a lag time of a 295 
further 30 minutes before onset of release. 296 
The effects of varying acidic pH on the subsequent release of ibuprofen from the 0.75% gellan gum 297 
fluid gel following transfer to pH 7.4 was also evaluated. It was found that the release of ibuprofen 298 
from a 0.75% gellan gum fluid gel was strongly affected by the pH of the dissolution media (Fig. 299 
9). There was no significant difference in release between samples that were initially exposed to pH 300 
4, pH 5, and pH 7.4. However, as the pH was decreased below the pKa of the carboxyl group of the 301 
gellan gum (~3.4), an acid gel was formed, preventing the dissolution of the gel, thus retarding 302 
ibuprofen release. This lag time became progressively more pronounced as the pH was dropped 303 
further and the acid gel strengthened; exposure to pH 1.2 for just 20 min prevented the onset of 304 
release for a further 60 min following transfer to pH 7.4. Moreover, there was a linear relationship 305 
between onset of release in pH 7.4 and the preceding exposure time at pH 1.2 for up to 120 min 306 
(Fig. 10). A linear relationship was also found following exposure to pH 2 although the effect was 307 
substantially less pronounced. This was thought to be due to fewer H+ ions present at pH 2 308 
compared with pH 1.2. This will result in formation of a weaker acid gel with an associated increase 309 
in hydration and dissolution of the ibuprofen when transferred to pH 7.4. Indeed, the stiffness of the 310 
gel had an exponential relationship with onset of release in pH 7.4 media (Fig. 11). Furthermore the 311 
stiffness of the gellan was dependent on the duration of exposure to acidic pH which has also 312 
recently been reported by Bradbeer et al. (2014). Interestingly, regardless of the duration of acid 313 
exposure, the stiffness of gellan fluid gels eventually plateaued at approximately 1200 Pa when 314 
transferred to pH 7.4 (Fig. 12).  Subsequently, the gel stiffness as a function of exposure time 315 
relates to in vitro release. When the gel was exposed to pH 1.2 for 60 min, G‟ was approximately 316 
8000 Pa and release was retarded, probably due to the time required for ion exchange to occur 317 
between the H+ cross-linked gel and the phosphate buffer. This exchange gradually reduces the gel 318 
strength until drug release is enabled. Moreover, the diffusion of the phosphate buffer into the gel 319 
also increases the solubility of the ibuprofen by increasing the pH within the gel. This is thought to 320 
have facilitated drug diffusion into the surrounding release medium increasing release rate as 321 
highlighted, with a much faster release rate of 0.44 mg/min when the exposure time in acid was 322 
only 10 min compared with 0.15 mg/min following 60 min exposure (Fig. 13). This dependence on 323 
acidic residence time and the strength of acidic pH may be problematic in determining reproducible 324 
pharmacokinetics between patients where gastro intestinal physiology can vary. Therefore strategies 325 
to overcome this issue would need to be addressed if such a carrier was to be used in clinical 326 
practice.  However, by understanding the three way relationship between acid exposure time, gel 327 
stiffness and onset of release, there is potential for controlling release behaviour by tuning the fluid 328 
gels to have a specified stiffness at a particular pH and duration of exposure. Furthermore, 329 
producing formulations using this relatively simple method is particularly attractive and by careful 330 
design of processing parameters, the microgel particles‟ size, shape, viscoelasticity and behaviour in 331 
physiological fluids can be manipulated to suit the application. This could open the door to multiple 332 
applications of fluid gel systems in pharmaceutical technology in addition to use as modified release 333 
oral liquids.    334 
 335 
5. Conclusion 336 
In this study we have demonstrated that fluid gels have the potential to be formulated with a similar 337 
viscosity profile to that of a marketed paediatric oral liquid with a yield stress sufficient that the 338 
sample can be inverted without any immediate flow but shear thins sufficiently by shaking, to be 339 
poured onto a dispensing spoon. Furthermore, we have shown that it is possible to modify the 340 
release of ibuprofen from gellan gum fluid gels, providing a simple and effective technology in 341 
formulating modified release oral liquids. The release behaviour of ibuprofen from gellan gum fluid 342 
gels in a simulated intestinal pH environment was dependent on the stiffness of the gel following 343 
exposure to simulated gastric pH media. The stiffness, and hence drug release, could be controlled 344 
with exposure time and acidity of the simulated gastric pH environment. This work highlights the 345 
potential application of gellan gum fluid gels as modified release oral liquids while at the same 346 
time, illustrates the importance of understanding how subtle differences in patient physiology could 347 
impact on drug release from such formulations. A realization of this is very important especially 348 
when designing medicines for paediatrics. 349 
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 442 
Figure Captions 443 
Figure 1 Viscosity of gellan gum during fluid gel formation (cooling at 2°C /min at a shear 444 
rate of 500 s-1) for 0.1% (filled diamonds) 0.375 % (open squares) 0.5% (open circles) 0.75% 445 
(filled triangles) and 1% (black crosses) w/v gellan gum loaded with 20 mg/ml ibuprofen.  446 
 447 
Figure 2 A) Viscosity vs. shear rate at 25°C for 0.1% (filled diamonds) 0.375 % (open squares) 448 
0.5% (open circles) 0.75% (filled triangles) and 1% (black crosses) w/v gellan gum loaded 449 
with 20 mg/ml ibuprofen. Black line indicates a proprietary ibuprofen paediatric suspension. 450 
B) Mechanical spectrum (0.5% strain; 37 °C) of a 0.75% Gellan Gum fluid gel loaded with 20 451 
mg/ml ibuprofen showing variation of G’ (filled squares), G’’ (open squares) and * (filled 452 
triangles) with angular frequency. 453 
Figure 3 Images illustrating the shear thinning behaviour of an ibuprofen loaded fluid gel 454 
sample with the ability to invert without any flow. 455 
 456 
Figure 4 Viscosity of 0.75% w/v gellan gum loaded with 20 mg/ml ibuprofen during fluid gel 457 
formation using A) different cooling rates; 10 °C/min (open circles), 2 °C/min (filled 458 
diamonds), 0.5 °C/min (open triangles) at a shear rate of 500 s-1 and B) different shear rates 459 
cooling at 2 °C/min; 1000 s-1  (open diamonds),  500 s-1  (filled diamonds), 100 s-1 (black 460 
crosses). 461 
 462 
Figure 5 Light microscopy images of gellan gum fluid gels prepared at different 463 
concentrations  loaded with 20mg/ml ibuprofen A) 0.1% w/v B) 0.5 % w/v C) 0.75 % w/v D) 1 464 
% w/v.  465 
 466 
Figure 6 Light microscopy images of 0.75% w/v gellan gum loaded with 20 mg/ml ibuprofen 467 
prepared at a shear rate of 500 s-1  using different cooling rates (A-C) A) 0.5 °C/min B) 468 
2°C/min C) 10 °C/min and different shear rates cooling at 2 °C/min (D-F); D)100 s-1  E) 500 s-1  469 
F) 1000 s-1  470 
 471 
Figure 7 Light microscopy images of gellan gum fluid showing crystallised ibuprofen 472 
entrapped within gel particles 473 
 474 
Figure 8 Cumulative % release of ibuprofen from fluid gels prepared at different 475 
concentrations of gellan gum compared with a standard ibuprofen suspension. Dotted line 476 
indicates the point the media was changed from 0.1 M HCl at pH 1.2 to PBS at pH 7.4. Values 477 
are represented as mean ± SD (n=3) 478 
 479 
Figure 9 Cumulative % release of ibuprofen from 0.75% w/v gellan gum fluid gel loaded with 480 
20 mg/ml ibuprofen exposed to different acidic pH values for a period of 20 minutes. Dotted 481 
line indicates the point the media was changed to PBS at pH 7.4. Values are represented as 482 
mean ± SD (n=3) 483 
 484 
Figure 10 Relationship between onset of release at pH 7.4 and preceding exposure time in 485 
simulated gastric fluid at pH 1.2 (filled diamonds) and pH 2 (open diamonds). 486 
 487 
Figure 11 Exponential relationship between the onset of release in SIF pH 7.4 as a function of 488 
gel stiffness (G’). 489 
 490 
Figure 12 Effect of time exposed to pH 1.2 on gel stiffness (G’) and subsequent stiffness on 491 
transfer to pH 7.4. The red line (filled diamonds) indicates the stiffness of the gel when 492 
exposed to pH 1.2 (0.5% strain; 37 °C at 10rad s-1). The green dashed line (open triangles) 493 
represents the stiffness of the gel in PBS at pH 7.4 following 10 min exposure to pH 1.2.  The 494 
blue dashed line (filled squares) represents the stiffness of the gel in PBS at pH 7.4 following 495 
60 min exposure to pH 1.2. 496 
 497 
Figure 13 Cumulative % release (primary vertical axis) and gel stiffness (G’) (secondary 498 
vertical axis) versus time following A) 60 min exposure to pH 1.2 and B) 10 min exposure to 499 
pH 1.2. 500 
 501 
 502 
 503 
 504 
Fig. 1.  505 
Viscosity of gellan gum during fluid gel formation (cooling at 2 °C/min at a shear rate of 500 s−1) for 0.1% (filled diamonds), 506 
0.375% (open squares), 0.5% (open circles), 0.75% (filled triangles) and 1% (black crosses) w/v gellan gum loaded with 507 
20 mg/ml ibuprofen. 508 
 509 
 510 
Fig. 2.  511 
(A) Viscosity vs. shear rate at 25 °C for 0.1% (filled diamonds), 0.375% (open squares), 0.5% (open circles), 0.75% (filled 512 
triangles) and 1% (black crosses) w/v gellan gum loaded with 20 mg/ml ibuprofen. Black line indicates a proprietary ibuprofen 513 
paediatric suspension. (B) Mechanical spectrum (0.5% strain; 37 °C) of a 0.75% gellan gum fluid gel loaded with 20 mg/ml 514 
ibuprofen showing variation of Gಿ (filled squares), Gೀ (open squares) and η* (filled triangles) with angular frequency. 515 
 516 
 517 
Fig. 3.  518 
Images illustrating the shear thinning behaviour of an ibuprofen loaded fluid gel sample with the ability to invert without any 519 
flow. 520 
 521 
 522 
Fig. 4.  523 
Viscosity of 0.75% w/v gellan gum loaded with 20 mg/ml ibuprofen during fluid gel formation using (A) different cooling rates; 524 
10 °C/min (open circles), 2 °C/min (filled diamonds), 0.5 °C/min (open triangles) at a shear rate of 500 s−1 and (B) different 525 
shear rates cooling at 2 °C/min; 1000 s−1 (open diamonds), 500 s−1 (filled diamonds), 100 s−1 (black crosses). 526 
 527 
 528 
Fig. 5.  529 
Light microscopy images of gellan gum fluid gels prepared at different concentrations loaded with 20 mg/ml ibuprofen (A) 530 
0.1% w/v, (B) 0.5% w/v, (C) 0.75% w/v and (D) 1% w/v. 531 
 532 
 533 
Fig. 6.  534 
Light microscopy images of 0.75% w/v gellan gum loaded with 20 mg/ml ibuprofen prepared at a shear rate of 500 s−1 using 535 
different cooling rates (A–C). (A) 0.5 °C/min, (B) 2 °C/min, (C) 10 °C/min and different shear rates cooling at 2 °C/min (D–F), 536 
(D) 100 s−1, (E) 500 s−1 and (F) 1000 s−1. 537 
 538 
 539 
Fig. 7.  540 
Light microscopy images of gellan gum fluid showing crystallised ibuprofen entrapped within gel particles. 541 
 542 
 543 
Fig. 8.  544 
Cumulative % release of ibuprofen from fluid gels prepared at different concentrations of gellan gum compared with a 545 
standard ibuprofen suspension. Dotted line indicates the point the media was changed from 0.1 M HCl at pH 1.2 to PBS at pH 546 
7.4. Values are represented as mean ± SD (n = 3). 547 
 548 
 549 
Fig. 9.  550 
Cumulative % release of ibuprofen from 0.75% w/v gellan gum fluid gel loaded with 20 mg/ml ibuprofen exposed to different 551 
acidic pH values for a period of 20 min. Dotted line indicates the point the media was changed to PBS at pH 7.4. Values are 552 
represented as mean ± SD (n = 3). 553 
 554 
 555 
Fig. 10.  556 
Relationship between onset of release at pH 7.4 and preceding exposure time in simulated gastric fluid at pH 1.2 (filled 557 
diamonds) and pH 2 (open diamonds). 558 
 559 
 560 
Fig. 11.  561 
Exponential relationship between the onset of release in SIF pH 7.4 as a function of gel stiffness (Gಿ). 562 
 563 
 564 
Fig. 12.  565 
Effect of time exposed to pH 1.2 on gel stiffness (Gಿ) and subsequent stiffness on transfer to pH 7.4. The red line (filled 566 
diamonds) indicates the stiffness of the gel when exposed to pH 1.2 (0.5% strain; 37 °C at 10 rad s−1). The green dashed line 567 
(open triangles) represents the stiffness of the gel in PBS at pH 7.4 following 10 min exposure to pH 1.2. The blue dashed line 568 
(filled squares) represents the stiffness of the gel in PBS at pH 7.4 following 60 min exposure to pH 1.2. (For interpretation of 569 
the references to colour in this figure legend, the reader is referred to the web version of this article.) 570 
 571 
 572 
Fig. 13.  573 
Cumulative % release (primary vertical axis) and gel stiffness (Gಿ) (secondary vertical axis) vs. time following (A) 60 min 574 
exposure to pH 1.2 and (B) 10 min exposure to pH 1.2. 575 
 576 
